For research use only. Not for therapeutic Use.
5-Aza-2′-deoxycytidine (Cat No.:I002785) is a nucleoside analog used as an epigenetic therapy for myelodysplastic syndromes (MDS) and certain leukemias. It works by inhibiting DNA methyltransferase, leading to hypomethylation of DNA and reactivation of tumor suppressor genes. This mechanism restores normal cell growth and differentiation in malignant cells. Decitabine is incorporated into DNA during replication, targeting rapidly dividing cells. Its ability to reverse aberrant DNA methylation patterns makes it an important therapeutic agent in hematologic malignancies, offering a targeted approach to managing abnormal gene silencing in cancer.
| Catalog Number | I002785 |
| CAS Number | 2353-33-5 |
| Synonyms | 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one |
| Molecular Formula | C₈H₁₂N₄O₄ |
| Purity | 98% |
| Target | DNMT1 |
| Target Protein | |
| Solubility | DMSO ≥43 mg/mL Water ≥9 mg/mL Ethanol ≥1.8 mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | 438 nM(HL-60); 4.38 nM(KG1a) |
| IUPAC Name | 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one |
| InChI | InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1 |
| InChIKey | XAUDJQYHKZQPEU-KVQBGUIXSA-N |
| SMILES | C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O |
| Reference | </br>1:Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia. Zhou S, Liu P, Zhang H.Mol Med Rep. 2017 May 12. doi: 10.3892/mmr.2017.6581. [Epub ahead of print] PMID: 28498449 </br>2:Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis. He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, Lian XY, Xu ZJ, Qian J, Lin J.Oncotarget. 2017 Apr 19. doi: 10.18632/oncotarget.17241. [Epub ahead of print] PMID: 28489568 Free Article</br>3:Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation. Niscola P, Abruzzese E, Trawinska MM, Palombi M, Tendas A, Giovannini M, Scaramucci L, Cupelli L, Fratoni S, Noguera NI, Catalano G, de Fabritiis P.Acta Oncol. 2017 May 10:1-2. doi: 10.1080/0284186X.2017.1324215. [Epub ahead of print] No abstract available. PMID: 28488914 </br>4:[Effects of decitabine on proliferation capacity and TFPI-2 expression in leukemia K562 cells]. Wang FJ, Li JJ, Xie HT, Zeng YY, Liu J, Zhang J.Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):340-343. doi: 10.3760/cma.j.issn.0253-2727.2017.04.016. Chinese. No abstract available. PMID: 28468099 </br>5:[A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine]. Ye L, Ren YL, Xie LL, Luo YW, Lin PP, Zhou XP, Ma LY, Mei C, Xu WL, Wei JY, Jiang HF, Zhang LM, Zeng H, Tong HY.Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):307-312. doi: 10.3760/cma.j.issn.0253-2727.2017.04.009. Chinese. PMID: 28468092 </br>6:Successful Management of Decitabine prior to Full-Dose Idarubicin and Cytarabine in the Treatment of Refractory/Recurrent Acute Myeloid Leukemia. Zhao H, Xu L, Yang Y, Shao J, Chen P, Dong X, Gu L, Li D.Acta Haematol. 2017 Apr 27;137(4):195-200. doi: 10.1159/000464013. [Epub ahead of print] PMID: 28445872 </br>7:Erratum: Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis [Corrigendum]. [No authors listed]Drug Des Devel Ther. 2017 Apr 10;11:1161. doi: 10.2147/DDDT.S139012. eCollection 2017. PMID: 28435228 Free PMC Article</br>8:Atrial fibrillation is associated with hypermethylation in human left atrium, and treatment with decitabine reduces atrial tachyarrhythmias in spontaneously hypertensive rats. Doñate Puertas R, Meugnier E, Romestaing C, Rey C, Morel E, Lachuer J, Gadot N, Scridon A, Julien C, Tronc F, Chapuis B, Valla C, Janin A, Pirola L, Méjat A, Rome S, Chevalier P.Transl Res. 2017 Jun;184:57-67.e5. doi: 10.1016/j.trsl.2017.03.004. Epub 2017 Mar 30. PMID: 28427903 </br>9:Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia. Niscola P, Neri B, Catalano G, Morino L, Giovannini M, Scaramucci L, Fratoni S, Noguera NI, Cordone I, de Fabritiis P.Acta Oncol. 2017 Feb 17:1-2. doi: 10.1080/0284186X.2017.1287947. [Epub ahead of print] No abstract available. PMID: 28406054 </br>10:Hypomethylation agent decitabine restores drug sensitivity by depressing P-glycoprotein activity through MAPK signaling pathway. Wang H, Wang X, Liao A, Liu Z.Mol Cell Biochem. 2017 Apr 12. doi: 10.1007/s11010-017-3022-0. [Epub ahead of print] PMID: 28405849 |
